This includes the ongoing Phase 3 HORIZON study of pelacarsen for Lp(a)-driven cardiovascular disease being developed by Novartis with data expected next year, and Bepirovirsen in Phase 3 ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

The other two major markets Ionis is targeting - this time with partners - are cardiovascular disease ("CVD"), through Pelacarsen, partnered with Swiss Pharma Novartis (NVS), and hepatitis B ...

It will need to move quickly to try to catch Novartis and its development partner Akcea – an affiliate of Ionis – which are developing an antisense-based candidate called pelacarsen (formerly ...

Novartis’ Akcea-partnered pelacarsen and Amgen’s olpasiran are both in phase 3 development, meaning they could reach the market in a couple of years. That’s important, as Lp(a) increases the ...

A half-dozen hospital systems plan to implement the tool, which combs through patient medical records to identify those ...

Pelacarsen Sodium is an antisense oligonucleotide commercialized by Novartis, with a leading Phase III program in Cardiovascular Disease. According to ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...

The European Broadcasting Union (EBU) is delighted to announce Novartis as an ‘Official Partner’ for the 69th Eurovision Song Contest when it’s hosted in their hometown in Basel, Switzerland, next May ...